alexa Recurrence rate of basal cell carcinoma after topical aminolevulinic acid-based photodynamic therapy.
Chemical Engineering

Chemical Engineering

Journal of Analytical & Bioanalytical Techniques

Author(s): Naidenov N, Dencheva R, Tsankov N

Abstract Share this page

Abstract Photodynamic therapy with topical 5-aminolevulinic acid is an alternative to the surgical treatment and radiotherapy of different non-melanoma skin cancers, especially basal cell carcinoma (BCC). Advantages of photodynamic therapy include selective destruction of the tumor; lack of toxicity; possibility to perform the procedure easily at any part of the human body; and single application, which is comfortable especially for elderly patients. Photodynamic therapy can be performed repeatedly without side effects and the cosmetic outcome is excellent. It is very convenient for large and multiple lesions and is the only choice for patients contra-indicated for surgery or radiotherapy. Disadvantage of photodynamic therapy is a relatively high recurrence rate of BCC after a single photodynamic procedure, ranging between 0\% and 100\%. We followed up a group of 60 patients with BCC who were treated with a single photodynamic procedure. The recurrence rate in our patients was 35\%. The most probable reasons for the relatively high recurrence rate were the size, localization, and histological type of the lesion; chemical structure of a photosensitizer used; the light source; and the dose. The lowest recurrence rate was observed in superficial BCCs.
This article was published in Acta Dermatovenerol Croat and referenced in Journal of Analytical & Bioanalytical Techniques

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version